Received: 25 November 2023
 Revised: 22 December 2023
 Accepted: 26 December 2023

 DOI: 10.48309/JMPCR.2024.427826.1044
 Accepted: 26 December 2023
 Accepted: 26 December 2023

FULL PAPER

Artificial intelligence (AI): Transformation in gestational diabetes mellitus (GDM) treatment in india

Bhole Nath Thakur 跑 | Ipseeta Satpathy 跑 | B. Chandra Mohan Patnaik 地 | Abhishek Kumar 跑

KIIT School of Management, KIIT University, Bhubaneswar, Odisha, India Gestational diabetes mellitus (GDM) refers to a condition characterized by varying degrees of glucose intolerance, which is initially identified during pregnancy. It is typically identified by conducting screenings on pregnant women to assess their clinical risk factors. Subsequently, among those deemed at risk, diagnostic tests are performed to evaluate their glucose tolerance. It is worth noting that women diagnosed with these diseases face an elevated likelihood of experiencing or developing diabetes outside of the pregnancy period. It refers to the occurrence of elevated blood glucose levels during pregnancy. The disease includes hyperglycaemia of varying degrees, ranging from pre-existing type 2 diabetes diagnosed during pregnancy to the development of full-blown GDM during pregnancy. It is associated with various adverse outcomes for both the mother and the new-born. These include increased birth weight and increased C-peptide levels in cord blood serum. In addition, having gestational diabetes puts you at a higher risk of developing diabetes in the future. The study's most important findings on awareness primarily affected respondents from cities -76.59%, in semi-urban areas it was 67.77% and in rural areas it was lowest -23.54%. The perception results show that the majority of respondents believe that AI has transformed healthcare services with lower costs and greater accuracy while providing other benefits.

Journal of Medicinal

and Pharmaceutical Chemistry Research (D) SAMI

* Corresponding Author:

Patnaik, B.Chandra Mohan Email: bcmpatnaik@gmail.com Tel: + 9668224322 KEYWORDS Gestational diabetes mellitus; experience; delivery of healthcare

Introduction

Gestational diabetes mellitus (GDM) is a condition characterized by varying degrees of glucose intolerance that occurs or is first recognized during pregnancy. It is widely acknowledged as one of the most prevalent clinical complications associated with pregnancy [1,2]. Based on the findings of the International Diabetes Federation (IDF) in

pregnancy;

2017, it is anticipated that the incidence of GDM will exhibit an upward trend over successive years [3]. It has been observed that women diagnosed with GDM may be susceptible to experiencing unfavorable consequences [4,5]. Mothers diagnosed with

patient

Artificial intelligence (AI): transformation ...

GDM face increased likelihood an of developing gestational hypertension and preeclampsia, as well as a higher risk of undergoing a cesarean section. In addition, they are at a heightened risk of developing subsequent type 2 diabetes mellitus (T2DM) and cardiovascular diseases, as supported by previous studies [6-11]. Infants born to women with GDM may exhibit an increased susceptibility to abnormal fetal development. It includes the occurrence of macrosomia, a condition characterized by excessive birth weight, a higher likelihood of congenital abnormalities [6,12-13]. Therefore, it is recommended that healthcare policymakers maintain a keen awareness of the importance of GDM in terms of its implications for early identification and subsequent intervention.

To date, a multitude of pertinent factors have been identified as predictors of this disease. Numerous studies have provided evidence supporting the association between gestational diabetes and GDM, and various risk factors. These commonly reported risk factors include advanced maternal age, prepregnancy obesity. A family history of diabetes (FHD), previous adverse obstetric outcomes such as macrosomia, stillbirth, abortion, premature delivery, congenital anomalies, being a primi-gravida, The history of GDM, infection factors such as Human Immunodeficiency Virus (HIV), smoking, and socio-economic factors such as educational level, occupation, and monthly household income.

Among the available polymorphisms, only the 5'UTR c.331 G>A is related to breast cancer in mastectomies and lumpectomies women [31-32]. Diabetes is a biological problem of life in a new way in human societies, especially in developing countries. Environmental and genetic factors are mutually influential in the incidence and exacerbation of this disease [32-33].

Artificial intelligence (AI) presents substantial prospects for advancement and innovation, as it effectively addresses Journal of Medicinal and Pharmaceutical - Chemistry Research

Page | 457

cognitive challenges that traditionally necessitate human intelligence. Voice recognition, recommendation systems, and self-driving cars exemplify the tangible achievements of AI across diverse fields. Probably, forthcoming advancements in the field of AI will yield even more substantial outcomes. According to a report by the International Data Corporation (IDC) [25].

it is projected that expenditure on AI will witness substantial growth, reaching an estimated value of 97.9 billion by 2023. The potential of AI in enhancing individuals' health and well-being is considerable, owing to the growing availability of electronic health records (EHRs) and other patient-related data. AI augment clinicians' diagnostic can identify opportunities processes, for prevention, and provide personalized treatment recommendations, among various other applications. Despite the existence of a few rudimentary assistive tools that have been implemented in practical settings [26-27].

The advent of AI has brought about a gradual transformation in the field of medical practice. The AI utilization in the medical domain has led to the development of numerous applications that find utility across various medical disciplines, including clinical, diagnostic, rehabilitative, surgical, and predictive practices. The field of medicine is witnessing significant advancements in clinical decision-making and disease diagnosis due to the integration of AI technologies. AI technologies can process and examine extensive amounts of data from various sources to identify diseases and provide guidance for clinical decision-making [28-29].

Role of AI in health care

This can increase healthcare productivity and efficiency, enabling healthcare systems to provide more and better care to more people. Artificial intelligence can help improve the experience of healthcare workers, allowing





Journal of Medicinal and Pharmaceutical Chemistry Research

them to spend more time on direct patient care and reduce burnout. Artificial intelligence offers the opportunity to reduce human errors, support professionals and medical staff, and provide patient care around the clock. As AI tools advance, AI can be used even more widely to read medical images, x-rays and scans, diagnose medical problems, and plans.

Objectives of the study

➢ To study the awareness level of GDM among pregnant women in the urban, rural, and semi-urban areas of the Mumbai region.

> To know the opinion of healthcare practitioners such as nursing, house surgeon, and assistant professors towards AI's role in GDM.

Sample size determination for unknown populations

N= Z^2 (P) (1-P)/ C^2 = (1.96)²(0.5) (1-0.5)/ (0.05)² = 384

Where, Z= Standard normal deviation set at 95% confidence level is 1.96, P= Percentage picking choice or response is 0.5, and the C= Confidence interval is 0.05

То gather the necessary data, а combination of cluster and random sampling methods was employed. A total of 783 individuals were initially approached for after participation. However, careful evaluation, it was determined that 387 respondents provided valid and complete responses, meeting the criteria for inclusion in the final dataset. To achieve a more comprehensive and accurate representation, all of the responses were included in the analysis. The study sample comprised 143 individuals who were pregnant at the time of data collection, while the remaining participants were identified as healthcare practitioners.

Here, NM stands for Nursing male, NF-Nursing female, HM- House surgeon male, HF-House surgeon female, APM- Assistant Professor Male, APF- Assistant Professor Female

According to Table 2, 38 were male nursing staff, 44 were female nursing staff, 36 were male house surgeons, 37 were female house surgeons, 43 were male assistant professors, and the rest were female assistant professors.

Research Design

Both primary and secondary data are used in this study. Pregnant women, nursing staff, house surgeons, and doctors of assistant professor level were considered as primary data. The total period is spread over six months. The variables were mostly derived from core group discussions and some were from the review of the literature. In this regard, eight core group discussions were made consisting of pregnant women, doctors, and nursing staff of various super specialty hospitals in study areas. Initially, more than 24 attributes were identified, however, after continuous deliberations with various groups, the attributes were finally restricted to 17 only. A simple weighted perception score method was for the various sub-variables used considered for the study. A 5-point Rensis

TABLE 1 Break up for sampling frame for awareness of GDM among pregnant women (143)

Urban areas of Mumbai Region	Rural areas of Mumbai Region	Semi-urban areas of Mumbai Region
56	42	45

Artificial intelligence (AI): transformation ...

Journal of Medicinal - and Pharmaceutical Chemistry Research Page | 459

TABLE 2 Number of respondents from different categories

	iser errespend		entegentes		
NM	NF	НМ	HF	APM	APF
38	44	36	37	43	46

Likert scale was used to measure each attribute. Weights of 5 for completely agreeing on responses, weights of 4 for agreeing on responses, weights of 3 for neutral stands, weights of 2 assigned for disagreeing responses, and weights of 1 assigned to completely disagreeing responses. Cluster and snowball sampling method used to collect the perceptions of the health care service providers and for the awareness level random sample being used. For confidentiality, the names of the hospitals were not disclosed.

Table 1, shows that in the urban areas, 56 respondents participated, in rural areas 42 respondents participated and the rest were from semi-urban areas.

Table 2, shows the various categories of respondents related to nursing, house surgeon and assistant professors.

Scope of the study

The present scope of the study includes various urban, rural, and semi-urban areas of Mumbai. The sample includes from the pregnant women associated with advertising sector. The pregnant women in advertising sector have to sit before the computers for long hours which leads to obesity& stress culminating in smoking which in turn spikes the blood glucose levels during pregnancy leading to GDM. The justification being, during the interaction with health care practitioners it was observed that this is one segment on whom not much study has been undertaken. The participants include male and female nursing staff, male and female house surgeons, and male and female assistant professors.

D) SAMI

Various localities of urban, rural and semiurban is mentioned in the Table 3.

In Figure 1, the awareness level of GDM in urban pregnant women was 59.63%, 12.96% in rural areas, and 36.17% in semi-urban areas. For the partial awareness level among pregnant women in urban areas 16.96%, 10.58% in rural areas, and the same for the semi-urban areas 31.60%. Similarly, 76.46% of rural areas pregnant women were not aware of GDM, 32.03% in semi-urban not aware of GDM, and 23.41% in urban areas.

The Maximum Possible Weight = responses X Variables X maximum weight In Table 4, the maximum possible weight and least possible weight were ascertained for various health care practitioners. The weight scores were used in Table 5- perception of health care practitioners

TABLE 3 Areas	considered in the M	umbai Region
---------------	---------------------	--------------

Urban areas of Mumbai Region	Rural areas of Mumbai Region	Semi-urban areas of Mumbai Region
Bandra west	Anik	Andheri
Borivali east	Borla	Marol
Kandivalli west	Kirol	Sahar
Colaba	Kopari	Akruli
Dadar west	Kurla	Gorai
Worli	Vikroli	Maroshi
Juhu	Nahur	Tulsi

Source: Mumbai ready reckoner




FIGURE 1 Awareness level of GDM **Source:** Annexures 1,2, and 3

Table 4 Computation of the Maximum Possible Weight (MPW) and the Least Possible Weight(LPW) for various health care practitioners

Weight	NM	NF	HM	HF	APM	APF
The Maximum Possible Weight	3230	3740	3060	3145	3655	3910
The Least Possible Weight	646	748	612	629	731	782

TABLE 5 Perception	of health care	practitioners
---------------------------	----------------	---------------

TABLE 5 T CICCPtion of health care	NM	NF	HM	HF	APM	APF
AI helps in better risk assessment for GDM	117	202	178	170	194	207
patients.						
AI helps in patient prognosis estimation and	116	195	171	168	189	201
treatment selection based on knowledge.						
AI helps with early detection by analysing a	131	197	174	164	193	207
patient's medical history of GDM patients.						
AI helps in test results to identify patterns	110	179	165	173	172	183
that may indicate the presence of GDM.						
AI facilitates diagnosis with high accuracy of	114	189	168	169	176	189
GDM.						
AI helps in predicting gene mutations from	132	182	180	172	178	197
historical analysis.						
AI offers immense potential for improving	127	189	173	161	181	199
patient care of GDM patients.						
AI assists medical professors and staff.	123	181	164	168	174	189
AI provides patient service 24x7 to GDM	125	186	170	173	180	201
patients.						
AI reduces human error in GDM treatment.	138	190	178	178	188	207
AI streamlines workflow in GDM treatment.	127	185	174	172	180	187
AI helps in easy information sharing for GDM	144	181	169	158	171	192
patients.						
AI reduces the overall cost of GDM treatment.	143	181	164	170	173	189
AI facilitates a lower risk of infections for	144	188	173	166	179	194
GDM patients.	144	100	1/3	100	1/)	174
-	130	192	177	165	187	199
AI provides less pain, scarring, and blood loss	120	192	1//	102	10/	199
to the GDM patients						

Artificial intelligence (AI): transformation		Journal of Medicinal - and Pharmaceutical - (D) SAMI -			Page	Page 461	
		Chemistry Research					
AI facilitates shorter hospitalization and faster recovery for GDM patients.	147	188	174	170	182	198	
AI helps in Quicker return to daily routines for GDM patients.	140	188	172	164	180	195	
Total weight	2208	3193	2924	2861	3077	3334	
The Maximum Possible Weight	3230	3740	3060	3145	3655	3910	
The Least Possible Weight	646	748	612	629	731	782	
% of total weight to the Maximum Possible	68.40%	85.37%	95.55%	90.97%	84.19%	85.27%	
Weight							
Average weight			84.9	6%			




FIGURE 2 Represents weight of different respondent groups

Figure 2, shows the perception weight of nursing male and female, weight of house ssurgeon male and female and for the assistant professor male and female.

Data interpretation

With reference to Table 5, The total weight of various health care practitioners such as NM, NF, HM, HF, APM, and APF were 2208, 3193,2924, 2861, 3077, and 3334 respectively. This shows that the percentage of actual total weight to maximum possible weight was 68.40%, 85.37%, 95.55%, 90.97%, 84.19%, and 85.27%. The average % was 84.96%. This indicates that even though the participants have majority of positive opinions, however, in the case of nursing males have less perception. This may be due to they were not equipped with the AI technology or may have less awareness about its benefits. The opinion may differ when we

take a different set of populations. The 84.96% signifies all the attributes considered for the present study having relevant for the current study.

Results

Related to awareness level, in the urban areas the awareness level among the respondents around 76.59% and the unaware level were 23.4%. For the rural segment 76.46% were not aware and rest were aware. There was a huge gap in the awareness level. Similarly, for the semi-urban areas the awareness level of fully and partially comes to 67.77% only.

As far as perceptions for the various attributes by different respondents, the perception level of HM were highest with 95.55% of maximum possible weight followed by the HF approximately 90.97%. At the same time for the NF and APF were more than 85%, similarly others also having significant

Page | 462

Journal of Medicinal and Pharmaceutical Chemistry Research




FIGURE 3 GDM

Source: Stock snaps

opinion base for the various attributes considered AI's relevance to the health care services as per the opinion of the various respondents.

4D) SAMI

Implications of the study

> More awareness among the pregnant women needs to be initiated more specifically in rural and semi-urban areas.

> Educate the AI biases to the staff and patients.

> Data security measures should be strengthened.

> Transparency can be enhanced on customised basis.

Figure 3, shows the the impact of gestational diabetes.

Conclusion

Gestational Diabetes Mellitus (GDS) is one of the challenges that healthcare practitioners face in recent times. However, through technological advancement, there are a lot of transformations in healthcare services. More specifically, the AI plays a crucial role in our life. This facilitates the GDM patients, risk assessment, accuracy in diagnosis, enhanced health care, and reduction in human error in addition to others. In this study, it was observed that there is a need for more awareness level of GMD affect in rural areas and sub-urban areas for the women working in the advertisement sector.

The male nursing staff and others who are not involving themselves in the adoption of AI technology should be encouraged to learn the same. This will provide an added advantage to the health care service. To conclude the findings, it was observed that house surgeon male female considers AI having more beneficial followed by assistant professor staff and nursing staffs.

Data inclusion and exclusion criteria

The participants in this study consisted exclusively of pregnant women, nursing staff, house surgeons, and assistant professors in the medical field. These individuals were selected based on their willingness to volunteer and their agreement to take part in data collection activities. The task of classifying the exclusion and inclusion criteria proved to be highly demanding, yet the diligent researchers successfully gathered the intended sample size.

Artificial intelligence (AI): transformation ...

Acknowledgments

The authors express their gratitude to all the participants comprising the nursing and house surgeon staff from various hospitals also the pregnant women of the advertising sector from a different demography. The invaluable feedback and active engagement of the participants greatly contributed to the successful completion of the current study.

Conflict of interest

The current study represents the collaborative efforts of the authors, who affirm that they do not possess any conflicts of interest with regard to any involved individuals or institutions. At present, no financial resources have been procured for the ongoing investigation.

Orcid

Bhole Nath Thakur: https://www.orcid.org/0009-0004-0053-3525 Ipseeta Satpathy: https://www.orcid.org/0000-0002-0155-5548 Patnaik, B.Chandra Mohan*: https://www.orcid.org/0000-0002-7927-0989 Abhishek Kumar: https://www.orcid.org/0000-0002-0876-3219

References

[1] T. A. Buchanan, A. H. Xiang, K. A. Page, Gestational diabetes mellitus: risks and management during and after pregnancy, *Nature Reviews, Endocrinology*, **2012**, *8*, 639–649. [Crossref], [Google Scholar], [Publisher]

[2] D. R. Coustan, Gestational diabetes mellitus, *Clinical Chem- istry*, vol. 59, no. 9, pp. 1310–1321, 2013. [Publisher]

[3] N. H. Cho, J. E. Shaw, S. Karuranga *et al.*, IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045, *Diabetes Research and Clinical Practice*, **2018**, *138*, 271–281. [Crossref], [Google Scholar], [Publisher]





[4] U. Kampmann, L. R. Madsen, G. O. Skajaa, D. S. Iversen, N. Moeller, and P. Ovesen, Gestational diabetes: a clinical update, *World Journal of Diabetes*, **2015**, *6*, 1065–1072. [Crossref], [Google Scholar], [Publisher]

[5] G. M. Brawerman, V. W. Dolinsky, Therapies for gesta- tional diabetes and their implications for maternal and off- spring health: evidence from human and animal studies, *Pharmacological Research*,2018, *130*, 52–73. [Crossref], [Google Scholar], [Publisher]

[6] B. E. Metzger, D. R. Coustan, E. R. Trimble, Hyperglyce- mia and adverse pregnancy outcomes, *Clinical Chemistry*, **2019**, *65*, 937-938. [Crossref], [Google Scholar], [Publisher] [7] Z. Li, Y. Cheng, D. Wang, Incidence rate of type 2 diabe- tes mellitus after gestational diabetes mellitus: a systematic review and meta-analysis of 170,139 women, *Journal Diabetes Research*, **2020**, *2020*, 1–12. [Crossref], [Google Scholar], [Publisher]

[8] Y. Yogev, E. M. Xenakis, and O. Langer, The association between preeclampsia and the severity of gestational diabetes: the impact of glycemic control, *American Journal of Obstetrics and Gynecology*, **2004**, *191*, 1655–1660. [Crossref], [Google Scholar], [Publisher]

[9] D. Marchetti, D. Carrozzino, F. Fraticelli, M. Fulcheri, and E. Vitacolonna, Quality of life in women with gestational dia- betes mellitus: a systematic review, *Journal Diabetes Research*, **2017**, *2017*, 1–12. [Crossref], [Google Scholar], [Publisher]

[10] E. Vounzoulaki, K. Khunti, S. C. Abner, B. K. Tan, M. J. Davies, and C. L. Gillies, Progression to type 2 diabetes in women with a known history of gestational diabetes: system- atic review and meta-analysis, *BMJ*, **2020**, *369*. [Crossref], [Google Scholar], [Publisher]

[11]R. Retnakaran, Y. Qi, P. W. Connelly, M. Sermer, B. Zinman, and A. J. Hanley, Glucose intolerance in pregnancy and post- partum risk of metabolic syndrome in young women, *The Journal of Clinical Endocrinology and*



B. N. Thakur et al

Archive of SID.ir

Page | 464

Journal of Medicinal – and Pharmaceutical Chemistry Research

Metabolism, **2010**, *95*, 670–677. [Crossref], [Google Scholar], [Publisher]

(D) SAMI

[12] R. Retnakaran , B. R. Shah, Glucose screening in preg- nancy and future risk of cardiovascular disease in women: a retrospective, population-based cohort study, *The Lancet Diabetes and Endocrinology*, **2019**, *7*, 378–384. [Crossref], [Google Scholar], [Publisher]

[13] T. D. Clausen, E. R. Mathiesen, T. Hansen *et al.*, High preva- lence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia, *Diabetes Care*, **2008**, *31*, 340– 346. [Crossref], [Google Scholar], [Publisher]

[14] A. W. Mwanri, J. Kinabo, K. Ramaiya, and E. J. Feskens, Ges- tational diabetes mellitus in sub-Saharan Africa: systematic review and metaregression on prevalence and risk factors, *Tropical Medicine & International Health*, **2015**, *20*, 983–1002. [Crossref], [Google Scholar], [Publisher]

[15]K. Cypryk, W. Szymczak, L. Czupryniak, M. Sobczak, andA. Lewiński, Gestational diabetes mellitus—an analysis of risk factors, *Endokrynologia Polska*, **2008**, *59*, 393–397. [Google Scholar], [Publisher]

[16] A. S. Anzaku , J. Musa, Prevalence and associated risk fac- tors for gestational diabetes in Jos, north-central, Nigeria, *Archives of Gynecology and Obstetrics*, **2013**, *287*, 859–863. [Crossref], [Google Scholar], [Publisher]

[17] T. O. Egbe, E. S. Tsaku, R. Tchounzou, and M. N. Ngowe, Prevalence and risk factors of gestational diabetes mellitus in a population of pregnant women attending three health facilities in Limbe, Cameroon: a crosssectional study, *The Pan African Medical Journal*, **2018**, 31. [Google Scholar], [Publisher]

[18] B. E. Feleke, Determinants of gestational diabetes mellitus: a case-control study, *The Journal of Maternal-Fetal & Neonatal Medicine*, **2018**, *31*, 2584–2589. [Crossref], [Google Scholar], [Publisher]

[19] a) J. Agah, F. Roodsarabi, A. Manzuri, M. Amirpour, andA. Hosseinzadeh, Prevalence and associated risk factors of gestational diabetes mellitus in a tertiary hospital in Iran, *Clinical and Experimental Obstetrics & Gynecology*, **2019**, *46*, 85–89. [Google Scholar], [Publisher] b) E.M.V. Athulya Chandran, N. Mathew Valooran, R. A. Kumar, A Recent Update on Pyridine Derivatives as a Potential Lead for Diabetes Mellitus, *Journal of Chemical Reviews*, **2023**, *5*, 159-182. [Crossref], [Publisher]

[20]. P. A. dos Santos, J. M. Madi, E. R. da Silva, D. de Oliveira Per- eira Vergani, B. F. de Araújo, and R. M. R. Garcia, Gestational diabetes in the population served by Brazilian public health care. Prevalence and risk factors, *Revista Brasileira de Gineco- logia e Obstetrícia / RBGO Gynecology and Obstetrics*, **2020**, *42*. [Crossref], [Google Scholar], [Publisher]

[21] A. Ganapathy, R. Holla, B. B. Darshan, Determinants of gestational diabetes mellitus: a hospital-based case-control study in coastal South India, *International Journal of Diabetes in Developing Countries*, **2021**, *41*. [Crossref], [Google Scholar], [Publisher]

[22] J. Jao, M. Wong, R. B. Van Dyke, Gestational diabe- tes mellitus in HIV-infected and -uninfected pregnant women in Cameroon, Diabetes Care, 2013, 36, 141-142. [Crossref], [Google Scholar], [Publisher] [23] A. A. Muche, O. O. Olayemi, and Y. K. Gete, Prevalence and determinants of gestational diabetes mellitus in Africa based on the updated international diagnostic criteria: a systematic review and meta-analysis, Archives of Public Health, 2019, 77, 36. [Crossref], [Google Scholar], [Publisher]

[24] A. B. Kirke, S. F. Evans, and B. N. Walters, Gestational diabe- tes in a rural, regional centre in south Western Australia: predictors of risk, *Rural and Remote Health*, **2014**, *14*, 63-71. [Google Scholar], [Publisher]

[25] International Data Corporation, Worldwide spending on artificial intelligence systems will be nearly \$98



Artificial intelligence (AI): transformation ...

billion in 2023, according to new IDC spending guide, **2019**. [Crossref], [Publisher]

[26] A. Rajkomar, E. Oren, K. Chen, A.M. Dai, N. Hajaj, M. Hardt, *et al.*, Scalable and accurate deep learning with electronic health records, *NPJ Digit. Med*, **2018**, *1*, 1–18. [Crossref], [Google Scholar], [Publisher]

[27] S. Tonekaboni, S. Joshi, M.D. McCradden, A. Goldenberg, October. What clinicians want: contextualizing explainable machine learning for clinical end use. In Machine learning for healthcare conference, **2019**, 359-380. [Google Scholar],

[Publisher]

[28] T.L. Rodziewicz, J.E. Hipskind, Medical error prevention, *StatPearls. Treasure Island (FL): StatPearls Publishing*, **2020**. [Google Scholar], [Publisher]

[29] R.J. Burton, M. Albur, M. Eberl, S.M. Cuff, Using artificial intelligence to reduce diagnostic workload without compromising detection of urinary tract infections, *BMC medical informatics and decision making*, **2019**, *19*, 1-11. [Crossref], [Google Scholar], [Publisher]

[30] A. Selmi, A. Zarei, W. Tachoua, H. Puschmann, H. Teymourinia, A. Ramazani, Synthesis and structural analysis of a novel stable quinoline dicarbamic acid: x-ray single crystal structure of (2-((4-((2-(carboxy (methyl) amino) ethoxy) carbonyl) quinoline-

Journal of Medicinal and Pharmaceutical Chemistry Research

(1) SAMI Page | 465

2-yl) oxy) ethyl)(methyl)-carbamic acid and molecular docking assessments to test its inhibitory potential against SARS-CoV-2 main protease, *Chemical Methodologies*, **2022**, 463-474. [Crossref], [Google Scholar], [Publisher]

[31] Kalvanagh, P. A., Kalvanagh, Y. A. 'Comparison of Exons 2 and 3 of DIRAS3 Gene in Mastectomies and Lumpectomies Women', *Eurasian Journal of Science and Technology*, **2023**, *3*, 154-164. [Crossref], [Publisher]

[32] Kalvanagh, P. A., Kalvanagh, Y. A. 'Designing the Cognitive Model of Survivors after Mastectomy', *International Journal of Advanced Biological and Biomedical Research*, **2023**, *11*, 72-81. [Crossref], [Publisher]

[33] H. Khajeh, A. Bahari, A. Rashki, TCF7L2 polymorphisms in type 2 diabetes, insight from HRM and ARMS techniques, *International Journal of Advanced Biological and Biomedical Research*, **2021**, 9, 204-214. [Crossref], [Google Scholar], [Publisher]

How to cite this article: Bhole Nath Thakur, Ipseeta Satpathy, B.Chandra Mohan Patnaik *, Abhishek Kumar, Artificial intelligence (AI): transformation in gestational diabetes mellitus (GDM) treatment in india. *Journal of Medicinal and Pharmaceutical Chemistry Research*, 2024, 6(4), 456-465. Link: http://jmpcr.samipubco.com/article_186165.html

Copyright © 2024 by SPC (<u>Sami Publishing Company</u>) + is an open access article distributed under the Creative Commons Attribution License(CC BY) license (<u>https://creativecommons.org/licenses/by/4.0/</u>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.